MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Stamakort Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Stamakort (Gastric Cytomax, 'A-10') is a Khavinson peptide bioregulator made from a complex of short peptides extracted from calf gastric mucosa at the St. Petersburg Institute of Bioregulation and Gerontology. Following Khavinson's peptide theory of aging, it is proposed to act as a tissue-specific signal that enters gastric cells and modulates gene expression to support normal mucosal proliferation, barrier function, and repair, rather than acutely blocking acid like a proton-pump inhibitor [PMID: 12374906; PMID: 34834147]. It is sold as a 10 mg oral capsule (with a sublingual drop form), typically taken 1-2 capsules daily before meals for a 30-day course repeated a few times per year. The amino-acid sequence is proprietary, pharmacokinetics are uncharacterized, and independent randomized evidence is essentially absent - most data come from the Khavinson group itself. Stamakort is not FDA- or EMA-approved; it is a Russian-registered dietary supplement and is offered elsewhere as a research product.
Reconstitute: Add 2 mL bacteriostatic water → 10 mg/mL concentration.
Typical dose: 10-20 mg/day orally (1-2 x 10 mg capsules), 30-day course; ~250-1,000 mcg/day in the educational SC model
Easy measuring: At 10 mg/mL, 1 unit = 0.01 mL = 0.1 mg (100 mcg) on a U-100 insulin syringe.
Storage: Capsules stored cool and dry, protected from light and moisture. Lyophilized peptide refrigerated or frozen; reconstituted solution refrigerated at 2-8 °C and used within ~4 weeks. Avoid repeated freeze-thaw.
Half-life: Not formally characterized. Short Khavinson peptides clear from plasma within minutes; the manufacturer attributes a weeks-to-months 'aftereffect' to gene-expression changes, the stated basis for short cyclic courses rather than continuous dosing.
Route: Oral 10 mg capsules (also a sublingual drop form), taken 10-15 minutes before meals. The subcutaneous reconstitution figures on this page are an educational measurement reference only, not the real-world route.
Status: Not FDA- or EMA-approved. Registered in Russia/CIS as a dietary supplement (BAA); investigational and educational only elsewhere - not a substitute for evidence-based gastric therapy.
About Stamakort
Stamakort (Gastric Cytomax, "A-10") is a Khavinson gastric-mucosa peptide bioregulator: a natural short-peptide complex extracted from calf gastric mucosa and sold to support stomach-lining function during gastritis, ulcer recovery, and age-related digestive decline [1][8]. Clinically it is taken ORALLY as a 10 mg capsule (or sublingual drops) before meals; the subcutaneous reconstitution figures below are an educational measurement reference only, not the real-world route, mirroring how this site models other oral bioregulators.\n\nFor the Stamakort dosage modeled here, we reconstitute a 20 mg vial with 2.0 mL of bacteriostatic water (10 mg/mL), so each U-100 insulin-syringe unit holds 100 mcg. A practical educational titration runs 250 mcg/day (~2.5 units) for the first two weeks, 500 mcg/day (~5 units) through the standard course, and up to 1,000 mcg/day (~10 units) for an intensive or repeat course [8]. The corresponding real-world protocol is 1-2 capsules (10-20 mg) once daily for a 30-day course, repeated two to three times per year.\n\nFrequency: Once daily. Stamakort is not FDA- or EMA-approved and is presented here for educational purposes only — not as medical advice or a substitute for evidence-based gastric therapy.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 2.0 mL of bacteriostatic water into a sterile insulin or reconstitution syringe.
Inject the water slowly down the inner wall of the 20 mg Stamakort vial; do not spray the stream directly onto the powder, and avoid vigorous shaking or foaming.
Gently swirl or roll the vial until the solution is completely clear; this yields a 10 mg/mL concentration (100 mcg per U-100 insulin-syringe unit).
Store refrigerated at 2-8 °C and draw the prescribed units per dose (250 mcg ~ 2.5 units, 500 mcg ~ 5 units, 1,000 mcg ~ 10 units).
Educational note: Stamakort is clinically taken ORALLY as capsules before meals - these subcutaneous reconstitution figures are a measurement reference only; if modeling a subcutaneous injection, insert into the abdomen, inject slowly without aspirating, and wait a few seconds before withdrawing the needle.
Interactive Stamakort Syringe Calculator
Currently visualizing the 20 mg vial reconstituted with 2 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 20mg dry powder in 2mL water yields 10.00 mg/mL. To evaluate a 250mcg dose, pull to 2.5 units (3 syringe ticks).
U-100 Syringe Representation
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Phase | Dose per injection | Units (per injection) |
|---|---|---|
| Weeks 1-2 (introductory titration) | 250 mcg | 3 units (0.03 mL) |
| Weeks 3-4 (standard 30-day course) | 500 mcg | 5 units (0.05 mL) |
| Intensive / repeat course | 1000 mcg (1 mg) | 10 units (0.10 mL) |
Administration guidelines: Refer to guidelines | 2 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 20 mg vial.
Peptide Vials (Stamakort, 20 mg each):
- checkEstimates based on a representative ~700 mcg/day mid-course dose in the educational SC model
- check8 weeks ~ 2 vials (40 mg total)
- check12 weeks ~ 3 vials (60 mg total)
- check16 weeks ~ 4 vials (80 mg total)
Insulin Syringes (U-100):
- checkPer week: 7 syringes (1 injection/day)
- check8 weeks: 56 syringes
- check12 weeks: 84 syringes
- check16 weeks: 112 syringes
Bacteriostatic Water (10 mL bottles): Use 2 mL per vial for reconstitution.
- check8 weeks (2 vials): 4 mL -> 1 x 10 mL bottle
- check12 weeks (3 vials): 6 mL -> 1 x 10 mL bottle
- check16 weeks (4 vials): 8 mL -> 1 x 10 mL bottle
- checkKeep a spare bottle on hand to cover priming and waste
Alcohol Swabs: One for the vial stopper plus one for the injection site each day.
- checkPer week: 14 swabs (2/day)
- check8 weeks: 112 swabs -> 2 x 100-count boxes
- check12 weeks: 168 swabs -> 2 x 100-count boxes
- check16 weeks: 224 swabs -> 3 x 100-count boxes
Mechanism of Action (MOA)
Stamakort belongs to the Khavinson family of peptide bioregulators ("cytomaxes") developed over four decades at the St. Petersburg Institute of Bioregulation and Gerontology. It is a natural peptide complex extracted from the gastric mucosa of young calves using a patented low-temperature, mild-acid extraction that preserves a mixture of short, low-molecular-weight peptides; the specific amino-acid sequence is proprietary and has not been publicly disclosed, so Stamakort is best described as an organ-specific peptide complex rather than a single defined molecule [1].\n\nThe proposed mechanism follows Khavinson's "peptide theory of aging." Short peptides (typically 2-4 residues, ~300-500 Da) are small enough to cross cell and nuclear membranes, where they are hypothesized to bind specific promoter regions of double-stranded DNA and modulate transcription of tissue-specific genes [1][2][3]. In vitro work with fluorescently labeled Khavinson peptides has documented penetration into the cytoplasm, nucleus, and nucleolus of human cells and sequence-selective interaction with DNA and oligonucleotides, providing a partial biophysical basis for the gene-regulation claim [4]. For a gastric bioregulator, the asserted downstream effects are normalization of proliferation and differentiation of gastric epithelial and parietal cells, support of mucosal-barrier and mucus production, and modulation of local inflammatory signaling - framed as "restoring" age- or disease-impaired gastric tissue rather than acutely suppressing acid the way a proton-pump inhibitor does [2][3].\n\nRoute and pharmacokinetics: clinically, Stamakort is an ORAL capsule (10 mg) taken 10-15 minutes before meals, with a sublingual drop formulation also marketed. The subcutaneous reconstitution figures on this page are an educational measurement convention used across this site, not a validated delivery route. Formal pharmacokinetics - absorption, oral bioavailability, distribution, and elimination half-life - have not been characterized in peer-reviewed Western journals. Short peptides are generally cleared from plasma within minutes, yet the Khavinson literature attributes a durable "aftereffect" lasting weeks to months to changes in gene expression rather than to sustained plasma concentrations, which is the stated rationale for short (10-30 day) cyclic courses repeated a few times per year [1][5].\n\nThe broader bioregulator program reports geroprotective and tissue-restorative effects - including roughly 20-40% increases in rodent lifespan across the peptide class and telomerase activation by the related pineal peptide epitalon - but these findings derive overwhelmingly from the Khavinson group and have limited independent replication [5][6]. Independent reviews of short peptides acknowledge their therapeutic promise while noting that organ-specific "DNA-binding bioregulator" claims remain mechanistically debated and under-validated by controlled trials [7]. Stamakort itself has not been evaluated by the FDA or EMA; it is sold in Russia and several CIS countries as a dietary supplement/parapharmaceutical and elsewhere as a research or nutraceutical product [7][8].
Clinical Trial Efficacy Highlights
- starKhavinson's foundational 2002 monograph established the principle behind Stamakort: tissue-specific short peptides extracted from a given organ stimulate cellular activity in that same organ, and a decline in such regulatory peptides with age is proposed to drive age-related tissue dysfunction (the 'peptide theory of aging'), positioning a gastric-derived complex as a putative regulator of gastric mucosa [1].
- starA systematic review of peptide regulation of gene expression by Khavinson and colleagues compiled evidence that short peptides can modulate the transcription of multiple genes and influence protein synthesis, the central mechanistic claim underlying every cytomax including Stamakort [2].
- starAshapkin and colleagues reported that Khavinson short peptides alter DNA methylation and gene-expression patterns in aging human cell cultures, offering an epigenetic framework for the bioregulators' proposed tissue-restorative action [3].
- starFedoreyeva and colleagues showed that fluorescently labeled short Khavinson peptides penetrate the cytoplasm, nucleus, and nucleolus of HeLa cells and interact specifically with deoxyribo-oligonucleotides and DNA in vitro, giving partial biophysical support to the cell-penetration and DNA-binding hypothesis [4].
- starAnisimov and Khavinson summarized animal data attributing roughly 20-40% extensions of mean lifespan and reductions in spontaneous tumor incidence to long-term cyclic administration of tissue-specific peptide bioregulators, the class to which Stamakort belongs; these geroprotective claims originate largely from the authors' own group and lack large independent replication [5].
- starWork on the related pineal cytomax epitalon demonstrated induction of telomerase activity and telomere elongation in human somatic cells, illustrating a plausible class-level gene-regulatory effect - though this evidence is for a different peptide and does not establish gastric-specific clinical benefit for Stamakort [6].
- starManufacturer and distributor materials cite an unpublished St. Petersburg clinical observation of 47 chronic-gastritis patients reporting major symptomatic improvement and normalized gastric acidity after a course of Stamakort; this report is not indexed in PubMed or peer-reviewed Western journals and should be treated as promotional rather than verified clinical evidence [8].
- starAn independent international review of short peptides concluded that the class holds therapeutic promise but that organ-specific bioregulator claims remain insufficiently validated by randomized controlled trials; consistent with this, Stamakort has not been evaluated by the FDA or EMA and has no internationally accepted clinical indication [7].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningStamakort is reported by manufacturers to be very well tolerated, with claims of 'no side effects, complications, or drug dependence'; however, independent safety data from controlled trials are essentially absent, so this favorable profile is not externally verified [8].
- warningBecause it is taken orally, mild gastrointestinal effects such as nausea, abdominal discomfort, belching, or altered bowel habits are plausible and consistent with the route, even if rarely formally documented.
- warningHypersensitivity or allergic reactions are possible given the bovine (calf gastric mucosa) origin of the peptide complex; people with known animal-protein allergies should be cautious.
- warningThe proposed broad modulation of gene expression raises a theoretical, uncharacterized risk of off-target effects in tissues other than the stomach; this concern is unquantified because human safety studies are lacking.
- warningUse during pregnancy, breastfeeding, and in children has not been studied and is generally advised against by manufacturers and distributors.
- warningCaution is warranted in people with active or treated malignancy: class-level claims of proliferative and telomerase-modulating activity have not been characterized for cancer safety in patients.
- warningIf the educational subcutaneous model is followed using research-grade lyophilized material, injection-site reactions (redness, swelling, itching) and infection from non-sterile technique or impure product are the main practical risks; sterile handling is essential.
- warningRegulatory/research status: Stamakort is NOT approved by the FDA or EMA. It is registered in Russia/CIS as a dietary supplement (BAA) and sold elsewhere as a research or nutraceutical product, and it is not a substitute for evidence-based gastric care such as proton-pump inhibitors or Helicobacter pylori eradication [7][8].
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical Stamakort dosage?expand_more
The standard real-world Stamakort dosage is 1-2 capsules (10-20 mg) once daily, taken 10-15 minutes before meals, for a 30-day course that is usually repeated two to three times per year; a sublingual drop form uses about 5-6 drops several times daily. The educational subcutaneous reconstitution model on this page maps that onto roughly 250-1,000 mcg/day. There is no FDA-approved dose - these figures come from manufacturer guidance, not controlled trials.
How do you reconstitute Stamakort in this educational model?expand_more
Although Stamakort is genuinely an oral capsule, this site models it as a subcutaneous reconstitution for measurement consistency. Draw 2.0 mL of bacteriostatic water into a 20 mg vial to make 10 mg/mL, so each U-100 insulin-syringe unit equals 100 mcg. At that concentration, 250 mcg is about 2.5 units, 500 mcg about 5 units, and 1,000 mcg about 10 units. Refrigerate the solution and use within roughly four weeks.
What is the Stamakort half life?expand_more
Stamakort's half-life has not been formally characterized in peer-reviewed pharmacokinetic studies. Khavinson short peptides are generally cleared from the bloodstream within minutes, but the developers attribute a durable 'aftereffect' lasting weeks to months to changes in gene expression rather than to sustained drug levels - which is why courses are short (10-30 days) and only repeated a few times per year rather than dosed continuously.
Can Stamakort be stacked with other Khavinson peptides?expand_more
In practice it often is. Stamakort is commonly combined with other digestive-system bioregulators such as Suprefort (pancreas), Svetinorm (liver), and Vladonix (thymus/immune) in longevity-style protocols. These combinations have not been evaluated in controlled trials, and combining with conventional gastric medications (PPIs, antacids, H. pylori therapy) has not been formally studied, so any stacking is experimental.
Is Stamakort FDA approved?expand_more
No. Stamakort is not approved by the FDA or the EMA for any medical indication. It is registered in Russia and several CIS countries as a dietary supplement / biologically active additive (BAA), not as a drug, and is sold elsewhere as a research or nutraceutical product. It should be regarded as investigational and educational, not a substitute for evidence-based gastric treatment.
Related Guides & Tools
Step-by-step references for reconstituting, measuring, and storing Stamakort, plus the universal dosing calculator.
Academic References & Study Citations
Khavinson VK. Peptides and Ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11-144. View Scientific Paper →
Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. View Scientific Paper →
Ashapkin VV, Linkova NS, Khavinson VKh, Vanyushin BF. Epigenetic mechanisms of peptidergic regulation of gene expression during aging of human cells. Biochemistry (Mosc). 2015;80(3):310-322. View Scientific Paper →
Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Mosc). 2011;76(11):1210-1219. View Scientific Paper →
Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149. View Scientific Paper →
Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592. View Scientific Paper →
Apostolopoulos V, Bojarska J, Chai TT, et al. A Global Review on Short Peptides: Frontiers and Perspectives. Molecules. 2021;26(2):430. View Scientific Paper →
Stamakort (A-10 stomach peptide bioregulator) - product information and administration guidance. CosmicNootropic (distributor). View Scientific Paper →